NEW YORK (GenomeWeb) – French immune molecular diagnostics firm ImmunID on Tuesday announced a deal with the Singapore Immunology Network (SigN) for research into immune competence.

Under the terms of the agreement, ImmunID will use its ImmunTracker and ImmunIG tests to evaluate T and B immune repertoire diversity in the blood of patients enrolled in a SigN-led clinical trial. The indication and therapeutic intervention being studied in the trial were not disclosed.

SigN is a research institute under Singapore's Agency of Science, Technology, and Research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.